Molecular Inflammation Board at the Center for Personalized Medicine
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Biologic Agent.
- Who it may be relevant to
- Registry conditions: Psoriasis (PsO), Psoriasis Arthritis, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Spondylarthropathies. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Germany
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Molecular Inflammation Board at the Centers for Personalized Medicine at the University Hospitals of Freiburg, Heidelberg, Tübingen and Ulm - A Multicenter Prospective Observational Study
Overview
Molecular Inflammation Board at the Center for Personalized Medicine
Detailed description
Molecular Inflammation Board at the Center for Personalized Medicine
The study objectives are:
To ensure a prospective documentation of all patients who are referred to the Molecular Inflammation Board in routine clinical care To prospectively ensure the documentation of MEB patients with an emphasis to clinical outcome parameters and further response assessments (e.g. peripheral immunmonitoring, imaging parameters) To prospectively assess patient-reported outcome of MEB patients To evaluate compliance to MEB suggestions in routine clinical care
Interventions
- Biological Biologic Agent
Intervention with biologic agents
Primary outcome measures
- Therapy persistence [Time frame: Through study completion, an average of 1 year]
Eligibility criteria
Inclusion criteria
- Chronic inflammatory disorder (PsO, PsA, SpA, IBD)
- Given informed consent
- 18 years of age
Exclusion criteria
- No capacity to consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
Germany · 1 center
- University Hospital of Tübingen - Center for Personalized Medicine — Tübingen
Identifiers
NCT: NCT07132333 · 482/2022BO1